The most frequent adverse events in the brentuximab vedotin group were peripheral sensory neuropathy ( 94 [ 56 % ] of 167 patients vs 25 [ 16 % ] of 160 patients in the placebo group ) and neutropenia ( 58 [ 35 % ] vs 19 [ 12 % ] patients ) .